Cancer patients win equal cost-sharing for pill vs. injection drugs
H.R. 4101 — Cancer Drug Parity Act of 2025 · Filed by Glenn Grothman (R-WI) · 29 cosponsors · Introduced Jun 24, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires employer health plans to treat oral cancer drugs the same way they treat intravenous cancer drugs—meaning patients cannot be charged higher copays, deductibles, or coinsurance for taking a pill at home versus getting an injection at a clinic. It applies to FDA-approved anticancer medications prescribed by doctors as medically necessary, and requires a Government Accountability Office study within two years to measure whether the rule actually reduces patient costs.
Why we flagged it
The bill's core function is to eliminate discriminatory cost-sharing between two delivery methods for the same therapeutic class of drugs, ensuring patients face equal financial barriers regardless of whether they take a pill or receive an injection. This is a consumer-protection measure, not a subsidy or carve-out.
What the text implies
- Plans may respond by raising copays/deductibles uniformly across BOTH oral and IV drugs rather than lowering oral costs, shifting the burden to all cancer patients while technically complying with parity.
- The bill does not address Medicare or Medicaid, leaving seniors and low-income patients potentially unprotected—a significant gap in cancer drug access equity.
The full analysis lists 4 implications of this text.
Who stands to gain
cancer patients (reduced out-of-pocket costs); oral anticancer drug manufacturers (increased demand/market share if oral drugs become more accessib